Stayble Therapeutics AB (STABL) — Cash Flow Reinvestment Rate

Latest as of December 2019: 0.00x

Stayble Therapeutics AB (STABL) has a Cash Flow Reinvestment Rate of 0.00x as of December 2019, reinvesting Skr0.00 (capex Skr0.00 ) from operating cash flow of Skr3.76 Million. Explore cash efficiency ratio of Stayble Therapeutics AB to assess how effectively this company generates cash.

Reinvestment Rate

0.00x

(Capex + Investments) / Operating CF

Total Reinvested

Skr0.00

Capex + Investments

Operating Cash Flow

Skr3.76 Million

SEK

Capital Expenditures

Skr0.00

SEK

Stayble Therapeutics AB Cash Flow Reinvestment Rate (2019–2019)

Historical reinvestment intensity for Stayble Therapeutics AB across 1 annual periods. Explore STABL debt coverage from operations to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Stayble Therapeutics AB (2019–2019)

Year-by-year capital reinvestment analysis for Stayble Therapeutics AB. For live market cap and broader valuation context, see how much is Stayble Therapeutics AB worth.

Year	Reinvestment Rate	Total Reinvested (SEK)	Operating CF	Capex	YoY Change
2019	0.00x	Skr1.00K	Skr289.39K	Skr0.00	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow